The extent of bipartisan congressional support for pharmacy benefit manager reform legislation is encouraging drug industry and other stakeholders to hope a bill can pass before the end of the year.
PBM Reform Legislation: PhRMA ‘Laser Focused’ On Passage This Year
But the prospects for attaching the legislation to a federal spending package in December will be dependent on the outcome of the upcoming elections.
More from PBMs
• By
An analysis of Medicare Part D and other data found that more than one-third of all pharmacy spending went through pharmacies owned by Cigna, CVS Health, Humana or UnitedHealth Group.
• By
The leader of the House Energy and Commerce Health Subcommittee has a plan for passing pharmacy benefit manager reforms, but Democrats are skeptical.
• By
The pharmaceutical industry has been quiet on Trump's early federal government overhauls that could harm the drug business, still betting he will help produce better results than Biden.
• By
Chairman-designee Andrew Ferguson likely will continue the commission’s investigation of PBMs during the next administration.
More from Government Payers
• By
An analysis of Medicare Part D and other data found that more than one-third of all pharmacy spending went through pharmacies owned by Cigna, CVS Health, Humana or UnitedHealth Group.
• By
The UK branded drug industry is calling for adjustments to be made to the UK voluntary scheme framework for branded medicines, after the payment rate increased to 22.9% for 2025. Meanwhile, the generics industry says the scheme is functioning “as intended” and opposes any changes.
• By
The development could highlight the power of competitive market forces over government price controls or suggest Medicare price negotiation is enhancing competitive market forces.